Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments, announced today the company has retained The Cervelle Group, a nationally known investor relations and public relations firm to manage the company's communications program with shareholders and the media. Cancer Therapeutics is compensating The Cervelle Group 75,000 shares of restricted common stock for the three (3) months of service.
The Cervelle Group (www.thecervellegroup.com), based in Orlando, FL, will focus on communicating with shareholders, prospective investors and the media concerning Cancer Therapeutics. They will also assist with the dispensing of information on the Company as well as its growth strategy and broadening the Company's visibility.
"Medicine and treatments for a variety of diseases and ailments are continuing to advance at a record pace, we believe the idea of what Cancer Therapeutics is based on is not only a valid story but is a real company with tremendous potential," said Rob M. Karbowsky, President of the Cervelle Group LLC. "Cervelle specializes in working with undiscovered companies who have solid management, a great story to tell and a significant upside for revenue generation -- CTHP has these characteristics."